Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1979 Oct;8(4):325–329. doi: 10.1111/j.1365-2125.1979.tb04713.x

The effects of repeated nocturnal doses of clobazam, dipotassium chlorazepate and placebo on subjective ratings of sleep and early morning behaviour and objective measures of arousal, psychomotor performance and anxiety.

I Hindmarch, A C Parrott
PMCID: PMC1429832  PMID: 41548

Abstract

1. Repeated nocturnal doses of 30 mg clobazam and dipotassium chlorazepate 15 mg showed no significant effects compared to matching placebo on tests of psychomotor performance and serial subtraction of numbers given in the morning and afternoon of the day following treatment. 2. Both active preparations improved the perceived quality of sleep compared to placebo. 3. A reduction in rated anxiety scores was found with clobazam on the afternoon of the day following treatment together with an elevation of critical flicker fusion thresholds. 4. Dipotassium chlorazepate was found to impair performance of a low level conceptual task but not to influence performance at a more difficult level.

Full text

PDF
327

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barzaghi F., Fournex R., Mantegazza P. Pharmacological and toxicological properties of clobazam (1-phenyl-5-methyl-8-chloro-1,2,4,5-tetrahydro-2,4-diketo-3H-1,5-benzodiazepine), a new psychotherapeutic agent. Arzneimittelforschung. 1973 May;23(5):683–686. [PubMed] [Google Scholar]
  2. Feurst S. I. Clorazepate dipotassium, diazepam and placebo in chronic anxiety. Curr Ther Res Clin Exp. 1973 Jul;15(7):449–459. [PubMed] [Google Scholar]
  3. Hindmarch I. A 1,4-benzodiazepine, temazepam (K 3917), its effect on some psychological parameters of sleep and behaviour. Arzneimittelforschung. 1975 Nov;25(11):1836–1839. [PubMed] [Google Scholar]
  4. Hindmarch I. A sub-chronic study of the subjective quality of sleep and psychological measures of performance on the morning following night time medication with temazepam. Arzneimittelforschung. 1976;26(11):2113–2115. [PubMed] [Google Scholar]
  5. Hindmarch I., Parrott A. C., Arenillas L. A repeated dose comparison of dichloralphenazone, flunitrazepam and amylobarbitone sodium on some aspects of sleep and early morning behaviour in normal subjects. Br J Clin Pharmacol. 1977 Apr;4(2):229–233. doi: 10.1111/j.1365-2125.1977.tb00699.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hindmarch I., Parrott A. C. The effect of a sub-chronic administration of three dose levels of a 1,5-benzodiazepine derivative, clobazam, on subjective assessments of sleep and aspects of psychomotor performance the morning following night time medication. Arzneimittelforschung. 1978;28(11):2169–2172. [PubMed] [Google Scholar]
  7. Hindmarch I. Some aspects of the effects of clobazam on human psychomotor performance. Br J Clin Pharmacol. 1979;7 (Suppl 1):77S–82S. doi: 10.1111/j.1365-2125.1979.tb04669.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kasich A. M. Chlorazepate dipotassium in the treatment of anxiety associated with chronic gastrointestinal disease. Curr Ther Res Clin Exp. 1973 Mar;15(3):83–91. [PubMed] [Google Scholar]
  9. Lapierre Y. D. Clinical and physiological assessment of chlorazepate, diazepam and placebo in anxious neurotics. Int J Clin Pharmacol Biopharm. 1975 Jun;11(4):315–322. [PubMed] [Google Scholar]
  10. Marjerrison G., Neufeldt A. H., Holmes V., Ho T. Comparative psychophysiological and mood effects of diazepam and dipotassium clorazepate. Biol Psychiatry. 1973 Aug;7(1):31–41. [PubMed] [Google Scholar]
  11. Nicholson A. N., Stone B. M., Clarke C. H. Effect of the 1,5-benzodiazepines, clobazam and triflubazam, on sleep in man. Br J Clin Pharmacol. 1977 Oct;4(5):567–572. doi: 10.1111/j.1365-2125.1977.tb00787.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Nicholson A. N., Stone B. M., Clarke C. H., Ferres H. M. Effect of N-desmethyldiazepam (nordiazepam) and a precursor, potassium clorazepate, on sleep in man. Br J Clin Pharmacol. 1976 Jun;3(3):429–438. [PMC free article] [PubMed] [Google Scholar]
  13. Parrott A. C., Hindmarch I. Factor analysis of a sleep evaluation questionnaire. Psychol Med. 1978 May;8(2):325–329. doi: 10.1017/s0033291700014379. [DOI] [PubMed] [Google Scholar]
  14. Rupp W., Badian M., Christ O., Hajdú P., Kulkarni R. D., Taeuber K., Uihlein M., Bender R., Vanderbeke O. Pharmacokinetics of single and multiple doses of clobazam in humans. Br J Clin Pharmacol. 1979;7 (Suppl 1):51S–57S. doi: 10.1111/j.1365-2125.1979.tb04665.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sandler K., Brunswick D., Digiacomo J., Mendels J. A preliminary evaluation of the anxiolytic activity of clobazam. Curr Ther Res Clin Exp. 1977 Jan;21(1):114–116. [PubMed] [Google Scholar]
  16. Wiersum J. Clorazepate dipotassium in anxiety: a double-blind trial with diazepam controls. Curr Ther Res Clin Exp. 1972 Aug;14(8):442–448. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES